Efficacy of statins in patients with STEMI depending on the T–786→C polymorphism of the endothelial NO-synthase gene promoter

April 7, 2020
662
Resume

The aim was to evaluate the efficacy of statins in STEMI patients depending on the T–786→C polymorphism of the eNOS gene promoter. Methods. It is a retrospective analysis of the database for 2003–2010. Patients with STEMI hospitalized within the first 24 hours of symptoms onset and assessed for –786TC eNOS gene polymorphism, were included. 65 patients were treated with statins (atorvastatin 20 mg or simvastatin 40 mg) starting from admission (group 1) and 92 patients did not received statins until discharge (group 2). Endothelium-dependent flow mediated dilatation was measured at admission and at day 7. Results. Statins decreased cholesterol concentration independent of eNOS genotype. In group 1, within 10 days of treatment, the level of total cholesterol decreased by 17.6% versus 4.3% in group 2 (p<0.01), and LDL cholesterol level decreased by 27.1% versus 6.1%, respectively (p<0.01). Significant improvement of flow mediated dilatation was observed in patients with –786TT-genotype treated by statins. –786TT-genotype was also associated with decreased risk of recurrent inhospital ischemic events (myocardial infarction and post-myocardial infarction angina) and acute heart failure in statin treated patients. There were no benefits of early statin treatment in patients with (TC + CC) genotypes. Conclusion. Moderate doses of statins initiated at day of admission effectively improve endothelial function and prevent in-hospital complications in STEMI patients with –786TT-genotype and does not affect these parameters in patients with –786TC- or –786CC-genotypes of eNOS gene.

References:

  • Abe K., Nakayama M., Yoshimura M. et al. (2005) Increase in the transcriptional activity of the endothelial nitric oxide synthase gene with fluvastatin: a relation with the –786T>C polymorphism. Pharmacogenet. Genomics, 15: 329–336.
  • Anderson T.J., Meredith I.T., Yeung A.C. et al. (1995) The effect of choleste­rol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. New Engl. J. Med., 332: 488–493. DOI: 10.1056/NEJM199502233320802.
  • Balakumar P., Kathuria S., Taneja G. et al. (2012) Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins? J. Mol. Cel. Cardiol., 52(1): 83–92. doi:10.1016/j.yjmcc.2011.09.014.
  • Beckman J.A., Creager M.A. (2006) The nonlipid effects of statins on endothelial function. Trends in Cardiovascular Medicine, 16(5): 156–162.
  • Bertrand M.E., Simoons M.L., Fox K.A.A. et al. (2002) Management of acute coronary syndromes in patients presenting without persistent ST segment elevation. The Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology. Eur. Heart J., 23: 1809–1840. DOI: 10.1053/euhj.2002.3385.
  • Berwanger O., Santucci E.V., de Barros e Silva P.G.M. et al. (2018) Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial. JAMA, 319(13): 1331–1340. doi:10.1001/jama.2018.2444.
  • Blazing M.A., De Lemos J.A., Dyke C.K. et al. (2001) The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. Am. Heart J., 142(2): 211–217. DOI: 10.1067/mhj.2001.116959.
  • Cannon C.P., Braunwald E., McCabe C.H. et al.; Pravastatin or Atorvastatin Evaluation and Infection Therapy — Thrombolysis in Myocardial Infarction 22 Investigators (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Eng. J. Med., 350: 1495–1504.
  • Chen S.M., Tsai T.H., Hang C.L. et al. (2011) Endothelial dysfunction in young patients with acute ST-elevation myocardial infarction. Heart Vessels, 26(1): 2–9.
  • Dangas G., Smith D.A., Unger A.H. et al. (2000) Pravastatin: an antithrombotic effect independent of the cholesterol-lowering effect. Thromb. Haemost., 83: 688–692.
  • Dupuis J., Tardif J.C., Cernacek P., Theroux P. (1999) Cholesterol reduction improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation, 99: 3227–3333.
  • Feron O., Dessy C., Desager J.P. et al. (2001) Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation, 103: 113–118.
  • Fonarow G.C., Wright R.S., Spencer F.A. et al.; National Registry of Myocardial Infarction 4 Investigators (2005) Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am. J. Cardiol., 96(5): 611–616.
  • Ghilardi G., Biondi M.L., DeMonti M. et al. (2002) Independent risk factor for moderate to severe internal carotid artery stenosis: TC mutation of endothelial nitric oxide synthase gene. Clin. Chem., 48(7): 989–993.
  • Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 360: 7–22. DOI:10.1016/S0140-6736(02)09327-3.
  • Ibanez B., James S., Agewall S. et al.; ESC Scientific Document Group (2018) 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J., 39(2): 119–177. doi: 10.1093/eurheartj/ehx393.
  • Ito D., Ito O., Mori N. et al. (2010) Atorvastatin upregulates nitric oxide synthases with Rho-kinase inhibition and Akt activation in the kidney of spontaneously hypertensive rats. J. Hypertens, 28: 2278–2288.
  • Kayikcioglu M., Turkoglu C., Kultursay H. et al. (1999) Combined use of pravastatin and thrombolytic agents in acute myocardial infarction. Pravastatin Turkish trial. Circulation, 100 (Suppl. I): 1–303.
  • Killip T., Kimbal J.T. (1967) Treatment of miocardial infarction in a coronary care unit a two year experientse with 250 patients. Am. J. Cardiol., 20: 457–464. DOI:10.1016/0002-9149(67)90023-9.
  • Kureishi Y., Luo Z.Y., Shiojima I. et al. (2000) The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nature Med., 6: 1004–1010.
  • Laufs U., Liao J.K. (1998) Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J. Biol. Chem., 273: 24266–24271.
  • Lefer A.M., Campbell B., Shin Y.K. et al. (1999) Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation, 100: 178–184.
  • Lenderink T., Boersma E., Gitt A.K., Zeymer U. et al. (2006) Patients using statin treatment within 24 h after admission for ST-elevation acute coronary syndromes had lower mortality than non-users: a report from the first Euro Heart Survey on acute coronary syndromes. Eur. Heart J., 27(15): 1799–804.
  • Mach F., Baigent C., Catapano A.L. et al.; ESC Scientific Document Group (2020) 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Heart J., 41(1): 111–188. doi: 10.1093/eurheartj/ehz455.
  • Martínez-González J., Raposo B., Rodriguez C. et al. (2001) 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibition prevents endothelial NO synthase downregulation by atherogenic levels of native LDLs: balance between transcriptional and posttranscriptional regulation. Arterioscler. Thromb. Vasc. Biol., 21: 804–809.
  • Nagassaki S., Sertorio J.T., Metzger I.F. et al. (2006) eNOS gene T–786C polymorphism modulates atorvastatin-induced increase in blood nitrite. Free Radic. Biol. Med., 41: 1044–1049.
  • Patti G., Pasceri V., Colonna G. et al. (2007) Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J. Am. Coll. Cardiol., 49: 1272–1278.
  • Prakash P., Khanna V., Singh V. et al. (2011) Atorvastatin protects against ischemia-reperfusion injury in fructose-induced insulin resistant rats. Cardiovasc. Drugs Ther. doi:10.1007/s10557-011-6312-x.
  • Ridker P.M., Rifai N., Miles J.S. et al. (2000) Lovastatin 20–40 mg/day lowers high sensitivity C-reactive protein levels in AFCAPS/TexCAPS. Circulation, 102 (Suppl.): 833.
  • Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet, 344: 1383–1389.
  • Schwartz G.G., Olsson A.G., Ezekowitz M.D. et al.; Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators (2001) Effects of atorvastatin on early recurrent ischaemic events in acute coronary syndromes. The MIRACL study: a randomized controlled trial. J. Am. Med. Assoc., 285: 1711–1718.
  • Souza-Costa D.C., Sandrim V.C., Lopes L.F. et al. (2007) Antiinflammatory effects of atorvastatin: modulation by the T–786C polymorphism in the endothelial nitric oxide synthase gene. Atherosclerosis, 193: 438–444.
  • Thijssen D.H., Black M.A., Pyke K.E. et al. (2011) Assessment of flow-mediated dilation in humans: a methodological and physiological guideline. Am. J. Physiol., 300: 2–12. doi: 10.1152/ajpheart.00471.2010.
  • Thompson P.L., Meredith I., Amerena J. et al. (2004) Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: the Pravastatin in Acute Coronary Treatment (PACT) trial. Am. Heart J., 148: e2.
  • Wassmann S., Laufs U., Bäumer A.T. et al. (2001) HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension, 37: 1450–1457.